Three studies reported results for head and neck cancers without information on specific anatomical subsite; among them, the pooled HR was 0.77 (95% CI: 0.65–0.93), suggesting an inverse association between CD4+ and mortality (Figure 2a). This evidence concerns the gene CD4 and head and neck cancer.